Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label adalimumab extension in non-infectious intermediate, posterior, or pan-uveitis
2009-016196-29Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- May 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in uveitis and Hyalitis, sponsored by Abbott Laboratories. Primary endpoint: Proportion of subjects with no new active inflammatory chorioretinal or retinal vascular lesions. Started May 2010; status: completed.
02
Drugs
03
Conditions
uveitisHyalitis
Beyond the preview
Go deeper on 2009-016196-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-016196-29.